drugset / Trial / NCT04176133

Entolimod on Immunosenescence in Healthy Geriatric Subjects Receiving Influenza Vaccination

NCT04176133

RandomizedParallel-groupDouble-blindPrevention

Summary

Researchers are evaluating the safety and effectiveness of a single administration of entolimod when administered at the same time as the influenza vaccine (flu vaccine).

Timeline

Start
2019-10-30
Primary completion
2022-03-30
Completion
2022-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Entolimod Unknown 1 ug Intramuscular
Subject Entolimod Unknown 3 ug Intramuscular
Subject Entolimod Unknown 10 ug Intramuscular
Background Influenza Virus Vaccine Vaccine Intramuscular

Indications

No indication recorded.